ANALYSIS: Filipino ADHD patients finally get diagnosed—only to struggle finding medication

Access issues to ADHD medications is also tied to broader gaps in specialized healthcare.

According to a 2025 report by the Philippine Society for Developmental and Behavioral Pediatrics, the country only has 98 developmental-behavioral pediatricians. That means there is only one specialist for every 12,000 patients.

But securing specialized psychiatric care in the country often falls outside standard health coverage. While entry-level health maintenance organizations and prepaid consultation plans are widely available, coverage for specialized psychiatric care can remain limited, with some patients facing longer waiting periods or relying on out-of-pocket consultations.

As a result, many neurodivergent patients are forced to pay between ₱1,500 to ₱5,000 per private psychiatric session just to reach the prescription stage.

And once they finally obtain that prescription, they are immediately met with the structural realities of the medication supply chain.

According to Nomedic’s 2025 clinical guide, ADHD medications such as methylphenidate—commonly known by brand names like Concerta or Ritalin—can be difficult to find in standard retail pharmacies.

The limited stock can be linked to Republic Act No. 9165 or the Comprehensive Dangerous Drugs Act of 2002, which classifies psychostimulants as dangerous drugs.

To prevent diversion and abuse, the law mandates that only one drug can be prescribed per form, refills are strictly prohibited, and the dispensing pharmacy must hold a specialized S-3 retail license from the Dangerous Drugs Board’s implementing arm, the Philippine Drug Enforcement Agency to legally stock and distribute.

However, under the DDB’s Board Regulation No. 3, series of 2013, and the updated Board Regulation No. 8, series of 2019, not every branch of a major pharmacy chain is legally authorized to handle dangerous drug preparations.

Outlets that choose to secure DDB accreditation are still subjected to regulatory oversight, which implements strict dispensing limits and meticulous inventory tracking to account for every single tablet and prevent diversion.

As a result, pharmacies often order them in conservative quantities. Importers must also secure approvals from agencies such as the Food and Drug Administration and the DDB before controlled medications can enter the market.

Neurodivergent Filipinos have since developed exhausting workarounds, going as far as contacting multiple pharmacy branches near them and regularly checking for incoming shipments.

While strict oversight from agencies such as the FDA and DDB remains a necessary public safety measure against the misuse and diversion of controlled substances, the resulting supply challenges can place an additional administrative burden on patients who rely on these medications for daily functioning.

READ: